US-based biopharmaceutical company Insmed Incorporated (Nasdaq:INSM) announced on Thursday that it has received the highest ranking in Science journal's 2024 Top Employers Survey.
The annual survey polls employees in the biotechnology, pharmaceutical and related industries to choose the 20 best employers and their driving characteristics. The results were based on around 6,500 responses from individuals located primarily across North America, Europe, and Asia/Pacific Rim.
Will Lewis, Insmed chair and CEO, said: "It is a tremendous honour to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year. This past year has been transformational for our company, as we've demonstrated the strength of our commercial and pipeline programmes, continued to fuel the innovation engine behind our early-stage research, and enhanced our culture while growing to more than 1,200 employees around the world."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA